Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of delays in initiating postoperative chemoradiation while determining the MGMT promoter-methylation statuses of patients with primary glioblastoma

29 Jul 2015

Abstract excerpt

BACKGROUND: The benefits of new innovations in glioblastoma therapies should not be curtailed as a result of delays in commencement of radiation therapy, caused by clinical circumstances as well as diagnostic procedures. This study evaluates whether delays in chemo-radiotherapy after surgery, while determining O6-methylguanine-DNA-methyltransferase (MGMT) promoter status, affect the survival rates of patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Metastases and Treatment
Share to Glioma Diagnosis and Treatment
Share to Radiomics and Machine Learning in Medical Imaging

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26223282
DOI: 10.1186/s12885-015-1545-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of delays in initiating postoperative chemoradiation while determining the MGMT promoter-methylation statuses of patients with primary glioblastomaPMID 26223282Read ↗

Timing Matters: Overall Treatment Time, Radiotherapy Interruptions, and Outcomes in glioblastomas – Prognostic Significance in Different Biological Sub- GroupsSemantic proximity Read ↗

Old Does Not Necessarily Mean Worse: Standard 6-Week Chemoradiation For Elderly Patients (≥ 70 Years) With Newly Diagnosed GlioblastomaSemantic proximity Read ↗

Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.Semantic proximity Read ↗

O6-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implicationsSemantic proximity Read ↗

The extent of resection and adjuvant treatment are beneficial to the outcome of secondary glioblastomaSemantic proximity Read ↗

Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.Semantic proximity Read ↗

Predictors of Tumor Dynamics Over a 6-Week Course of Concurrent Chemoradiotherapy for Glioblastoma and the Effect on Survival.Semantic proximity Read ↗

Experience about Chemoradiation treatment with or without Concurrent Tumor-Treating Fields (TTFields) in Newly Diagnosed Glioblastoma (GBM) Patients in ChinaSemantic proximity Read ↗

How do delays in treatment affect patient prognosis in head and neck cancer?Semantic proximity Read ↗

Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).Semantic proximity Read ↗

On optimal temozolomide scheduling for slowly growing gliomasSemantic proximity Read ↗

Six-month mortality has decreased for patients with curative treatment for head and neck cancer in SwedenSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.